Sax Wealth Advisors LLC Purchases 1,485 Shares of Danaher Co. (NYSE:DHR)

Sax Wealth Advisors LLC increased its holdings in Danaher Co. (NYSE:DHR) by 83.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,260 shares of the conglomerate’s stock after acquiring an additional 1,485 shares during the period. Sax Wealth Advisors LLC’s holdings in Danaher were worth $748,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Decker Retirement Planning Inc. purchased a new stake in shares of Danaher during the 4th quarter valued at $31,000. Teachers Insurance & Annuity Association of America purchased a new position in Danaher in the third quarter valued at about $39,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher in the third quarter valued at $40,000. FSA Wealth Management LLC purchased a new stake in Danaher during the third quarter valued at about $50,000. Finally, Darwin Wealth Management LLC bought a new position in Danaher in the 3rd quarter worth approximately $55,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Guggenheim initiated coverage on Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 price target on the stock. Robert W. Baird dropped their price target on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Royal Bank of Canada dropped their target price on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Stephens reiterated an “overweight” rating and set a $315.00 price target on shares of Danaher in a research report on Wednesday, October 23rd. Finally, Scotiabank assumed coverage on shares of Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price target for the company. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Stock Performance

Shares of DHR opened at $238.41 on Friday. The firm has a market capitalization of $172.20 billion, a PE ratio of 45.50, a price-to-earnings-growth ratio of 4.23 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The company has a 50-day simple moving average of $234.85 and a two-hundred day simple moving average of $253.32. Danaher Co. has a one year low of $222.53 and a one year high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. Danaher’s quarterly revenue was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.02 earnings per share. On average, analysts anticipate that Danaher Co. will post 7.49 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. Danaher’s payout ratio is presently 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.